Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.
- Posts: 1
- Joined: Wed Mar 22, 2017 7:57 am
Thank you for your input! We truly appreciate your time and your feedback.
Last edited by CaseyStratisGRP
on Sun Mar 26, 2017 7:25 am, edited 2 times in total.
- Volunteer Moderator
- Posts: 5419
- Joined: Sat Nov 20, 2004 3:00 pm
Stratis Group wrote:
About Our Company
The biopharmaceutical landscape is constantly evolving and casting new light on how manufacturers must think about and manage their portfolio.
At Stratis Group, we bring together a long history of developing and delivering focused strategy for clients, with engagement targets ranging from some of the largest and most complicated brands to early-stage portfolios.
Our team has decades of experience in the pharmaceutical industry, with a foundation in both industry and consulting. Every individual brings a range of cross-functional experience across managed care, academic research, finance, public health, and hospital administration.
While becoming a part of our clients’ teams, we thrive on solving complex brand challenges that require both deep experience and innovative thinking.